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Similar to other epithelial appendages, mammary anlagen progress from stratified epithelium through placode
and bud stages. Embryonic mammary morphogenesis is elicited by a combination of local cell migration,
adhesion changes and proliferation, and these same developmental processes impact breast cancer etiology.
The Erbb signaling network plays important roles in postnatal mammary gland morphogenesis and
carcinogenesis. Neuregulin3 (Nrg3), an Erbb family ligand, has recently been shown to be involved in the
specification of mammary glands in mice. To further examine the possible involvement of other Erbb family
members and their ligands in early mammary morphogenesis, we have characterized their expression patterns
during this process. We used whole mount in situ hybridization to analyze the expression patterns of these
genes at stages prior to and during mammary placode formation. Immunohistochemistry was used to examine
expression patterns at later bud stages. The Neuregulin ligands, Nrg1, Nrg2, Nrg3, Nrg4 and the receptors,
Erbb1, Erbb2, Erbb3, Erbb4, were expressed either at stages prior to morphological appearance of the mammary
placode or from the time that the placode is first morphologically distinct through to later bud stages. The
expression patterns presented here suggest that multiple members of this signaling network are potential
mediators of early mammary morphogenesis.
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INTRODUCTION
Neuregulins are a family of ligands containing Egf-like
domains that signal through the Erbb receptor tyrosine
kinases to activate downstream signaling pathways such as
phosphatidyl inositol 3 kinase and mitogen-activated protein
kinase. This network of ligands and receptors mediates a
wide range of processes that have relevance to both
embryonic development and cancer, including cell adhesion,
differentiation, proliferation, migration and death (Yarden
and Sliwkowski, 2001). The Erbb signaling network also plays
significant roles in postnatal mammary gland development
(Troyer and Lee, 2001; Stern, 2003). Studies of mammary
tissue from Erbb1 and Erbb2-null mouse models have shown
that these genes have important roles during mammary ductal
outgrowth and morphogenesis (Wiesen et al., 1999; Jackson-
Fisher et al., 2004; Andrechek et al., 2005; Sternlicht et al.,
2005). Furthermore, Erbb4 is required for terminal diffe-
rentiation of the mammary gland and lactation fails in its
absence (Long et al., 2003; Tidcombe et al., 2003). Impaired
mammary epithelial proliferation and lobuloalveolar defects
are observed in Nrg1a-null mice but their mammary glands
are capable of sustained lactation (Li et al., 2002). Amphire-
gulin-null mice display severe ductal outgrowth defects at
puberty but lactate effectively (Luetteke et al., 1999).
Although mice mutant for the genes encoding Egf and Tgfa
display no apparent mammary defects when these genes are
singly mutated, compound null mutations for Amphiregulin,
Egf, and Tgfa display severe lactation defects (Luetteke et al.,
1999). These observations suggest that this network plays key
roles during development and that compensatory functions
are likely to exist so that in the absence of one ligand or
receptor, another may substitute.
In addition to roles in mammary epithelial development,
the Erbb receptors have profound relevance to breast cancer
(Holbro et al., 2003). Twenty to thirty percent of breast cancers
display overexpression and/or amplification of HER2/Erbb2,
which confers a poor prognosis (Berger et al., 1988; Slamon
et al., 1989). The HER2-targeted therapeutic, trastuzumab
(Herceptin), has shown a significant survival benefit in clinical
trials (Baselga et al., 1996; Cobleigh et al., 1999; Smith, 2001;
Harries and Smith, 2002). Furthermore, mouse models that
overexpress Erbb2 effectively mimic human breast cancer
(Hutchinson and Muller, 2000). Therefore, it appears that
some features of the Erbb pathway act in a similar manner in
both the human breast and mouse mammary gland.
Mammary placodes are thought to arise as a result of local
cell migration (Propper, 1978) and early stages of placode
formation are characterized by epithelial stratification
(Balinsky, 1950), which requires a proliferative basal
epithelium (Smart, 1970; Lechler and Fuchs, 2005). The
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initiation of mammary morphogenesis is believed to be
elicited by signals arising from the dermis (Sakakura, 1987;
Cunha and Hom, 1996). After the mammary epithelial bud
forms, it induces the surrounding mesenchymal cells to form
specialized mammary mesenchyme (Sakakura, 1987). The
mammary bud then forms a primary sprout and grows
downward to the mammary fat pad, the secondary mammary
mesenchyme (Sakakura, 1987), which sustains the growth of
mammary epithelial cells, including outgrowths from single
mammary epithelial stem cells (Shackleton et al., 2006). By
the end of gestation in the mouse, a rudimentary ductal tree
has formed, embedded within the fat pad (Sakakura, 1987).
Placode morphogenesis is governed by molecules that alter
cell adhesion dynamics and, in most cases, proliferation of
pluripotent epithelial cells (Blanpain and Fuchs, 2006;
Mikkola and Millar, 2006). As with the development of all
epidermal appendages, undifferentiated stem cells are
committed to specific lineages, and a population of cells
with a high capacity for proliferation is delimited, which
subsequently differentiates (Olivera-Martinez et al., 2004;
Blanpain and Fuchs, 2006; Watt et al., 2006).
Our previous studies indicated that Nrg3 promotes the
differentiation of squamous epithelium into mammary
epithelium (Howard et al., 2005). In the mouse embryo,
Nrg3 appears to regulate epithelial stratification and the
formation of local epithelial aggregations at the sites that
mammary placodes will form. Mice harboring the ska
mutation, a hypomorphic allele of Nrg3, often fail to form
placode 3, which can be restored after culture with
recombinant Egf domain of Nrg3. Furthermore, we have
recently found that mis-expressing Nrg3 throughout the
developing epidermis using the K14 promoter in a transgenic
mouse model results in the formation of ectopic mammary
glands (Panchal et al., in press). Nrg3 may promote mammary
placode formation by influencing the balance between stem
cell renewal, lineage selection and differentiation. As Nrg3 is
a member of a complex signaling network, it seems plausible
that signals from multiple ligands and receptors may be
integrated to regulate epidermal homeostasis and cell fate.
Therefore, we sought to investigate further expression of the
Neuregulin and Erbb family members during early mammary
morphogenesis.
RESULTS
Localization of the Erbb receptors during early mammary
morphogenesis
To study expression patterns of the Erbb receptors and their
ligands in the developing mammary gland (prior to and as it
initially forms), we studied pre-placode and placode stages.
We present data for placode 3 due to the ease of locating this
site in vibratome sections and since it is the first of the five
mammary placodes to become morphologically evident.
However, we did not observe significant differences in
expression among the other four mammary placodes that
were also observed and assessed. In Figure 1, the approx-
imate plane of the cross sections through the future site
of mammary placode 3 is shown in E11.0 C57BL/6 (B6)
embryos (Figure 1a) and at mammary placode 3 in E11.5 B6
embryos (Figure 1b). Later bud stages were analyzed from
sagittal sections from E12.5, E13.5, and E14.5 B6 embryos
(Figure 1c–h).
Prior to the formation of the mammary placode at E11.0,
Erbb1 is expressed throughout the surface ectoderm (Figure
2a and b). Erbb1 transcripts are observed throughout the
epidermis and expression is especially intense in the surface
ectoderm along the flank above the Wolffian ridge at the time
the mammary placode is first morphologically distinct at
E11.5 through E12.0 (Figure 2c–e). Erbb1 is expressed in all
surface epithelium at E12.0, including that of the mammary
bud proper (Figure 2f). From E12.5 to E13.5, Erbb1 and Erbb1
expression is weak in the mammary bud and the adjacent
epithelium (Figure 2g–i). At E13.5, Erbb1 is expressed in
mesenchyme directly adjacent to the mammary mesenchyme
on both the dorsal and ventral edges of the mammary bud
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Figure 1. Stages of early mouse mammary gland morphogenesis.
An example of a C57BL/6 (B6) embryo processed for whole mount in situ with
Erbb3 as probe at (a) E11.0 and (b) E11.5. The dotted line denotes the level of
the vibratome sections shown in subsequent figures. Examples of sagittal
sections used in the immunohistochemical study stained with hematoxylin
and eosin at (c) E12.5, (d) E13.5, and (e) E14.5 are shown and the location of
the mammary bud 4 is indicated with a black box. Magnified images of the
mammary bud are shown at (f) E12.5, (g) E13.5, and (h) E14.5. Bars¼ 1mm in
(a and b); 500 mm in (c–e); 30 mm in (f); 45mm in (g); 50 mm in (h).
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(Figure 2i). At E14.5, Erbb1 is expressed throughout the
mammary bud and surface epithelium and is expressed at
very low levels throughout the dermal mesenchyme except
for the mammary mesenchyme, where no Erbb1 expression is
detected (Figure 2j).
Erbb2 is expressed very broadly throughout the embryo at
E11.0. Erbb2 expression is detected in the surface ectoderm
along the flank at the future sites of the mammary placodes
and very broadly in the mesenchyme in embryos at stages
prior to the formation of the mammary placode (Figure 3a
and b). Broad expression of Erbb2 during embryogenesis at
E11.0 was confirmed with immunohistochemistry (Figure 3c).
We previously showed strong Erbb2 expression in the early
mammary placode and slightly less intense expression in the
adjacent mesenchyme (Howard et al., 2005). As the placode
matures, Erbb2 is expressed in the mammary bud and
adjacent epithelium (Figure 3d). At the late bud stage
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Figure 2. Erbb1 expression in the developing mammary gland. Expression
patterns at the site of placode 3 from whole mount in situ with Erbb1 as probe.
(a) E11.0, vibratome cross section (70 mm) across level where number 3
mammary anlage will form. (b) The presumptive mammary region is boxed
and shown magnified. Erbb1 is expressed in the entire surface ectoderm of the
embryo. Arrowhead denotes expression along presumptive mammary
placode 3 region. (c) E11.5, vibratome cross section (70 mm) at the
level of mammary placode number 3. (d) The mammary placode is boxed
and shown magnified. Arrowheads denotes epithelial expression of
Erbb1 along and adjacent to mammary placode 3. (e) E12.0, vibratome
cross section (70mm) of mammary placode number 3 also shows
epithelial expression of Erbb1 along and adjacent to mammary placode 3
(arrowheads). (h) E13.0, vibratome cross section (70 mm) of mammary
placode number 3. Erbb1 is expressed in the dermal mesenchyme (arrows)
flanking the mammary bud and at lower levels in the mammary bud and
adjacent epithelium (arrowheads) and at the site of the future fat pad
(asterisks) (h). Erbb1 expression at (f) E11.5, mammary bud 3, (g) E12.5
mammary bud 4, (i) E13.5 mammary bud 4, (j) E14.5 mammary bud 4.
At E11.5, Erbb1 is expressed in the entire surface epithelium of the embryo
(arrows), including the periderm of the mammary bud (arrowhead) (f).
At E12.5, Erbb1 expression is lower in the mammary bud epithelium
(arrowheads) than in the adjacent epithelium (arrows) (g). At E13.5, Erbb1 is
expressed in the dermal mesenchyme (arrows) flanking the mammary bud
and at low levels in the mammary bud and adjacent epithelium (arrowheads)
and at the site of the future fat pad (asterisks) (i). At E14.5, Erbb1 is expressed
throughout the surface epithelium and mammary bud epithelium
(arrowheads) and in the dermal mesenchyme (arrows), but not in the
mammary mesenchyme surrounding the mammary bud (j). The future fat
pad is denoted by three asterisks in (g–j). Bars¼ 600mm in (a); 210mm in
(b); 700mm in (c); 350mm in (d); 30 mm in (e and f); 40 mm in (g); 45mm in
(h and i); 50 mm in (j).
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Figure 3. Erbb2 expression in the developing mammary gland. Expression
patterns at the site of mammary placode 3 from whole mount in situ with
Erbb2 as probe. (a) E11.0, vibratome cross section (70 mm) at the level where
number 3 mammary anlage will form. The presumptive mammary region is
boxed and shown magnified in (b). (b) Erbb2 is expressed in the epithelium
(arrowheads) along the Wolffian ridge and in the underlying somite. Erbb2
expression at (c) E11.0, (d) E12.0 mammary bud 2, (e) E13.5 mammary bud 4,
and (f) E14.5 mammary bud 4. Erbb2 is expressed broadly in the embryo at
E11.0, including in the dorsal root ganglion, motor neurons, atrium, ventricle,
urogenital ridge, somite, and mesenchyme (c). Erbb2 is expressed in the early
mammary bud (arrows) and in the periderm (arrowheads) and at the site of the
future fat pad (asterisks) at E12.0. (d) At E13.5, Erbb2 is expressed in the
periderm (arrowhead) and the basal layer of the surface epithelium and of the
mammary bud (arrows) and at the site of the future fat pad (asterisks) (e).
At E14.5, Erbb2 is expressed at low levels in the mature mammary bud
(arrowhead) and at the site of the future fat pad (asterisks) and at moderate
levels in the neck of the mammary bud and in the adjacent surface epithelium
(arrows) (f). at, atrium; drg, dorsal root ganglia; mn, motor neuron; nt, neural
tube; s, somite; u, urogenital ridge; v, ventricle. Bars¼100 mm in (a); 50 mm in
(b); 600mm in (c); 25 mm in (d); 45 mm in (e); 50mm in (f).
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(E13.5), Erbb2 expression appears strongest at the basal
junction of the epithelium and mesenchyme in both the
surface epithelium and mammary bud (Figure 3e). By E14.5,
Erbb2 is expressed at moderate levels in the surface
epithelium and neck of the mammary bud and at lower
levels within the mature mammary bud (Figure 3f).
Erbb2 expression is observed in the mesenchyme in the
vicinity of the future site of the fat pad from E12.0 through
E14.5 (Figure 3d–f).
Erbb3 is expressed in the derivatives of the neural crest,
the dorsal root ganglion and Schwann cells (Figure 4a). Erbb3
is strongly expressed throughout the epithelium and in the
myotome at the site where placode 3 will form (Figure 4a and
b). At the early mammary placode stage, epithelial Erbb3
expression is mainly confined to the placode and adjacent
epithelium (Figure 4c and d). At E11.5, weak Erbb3
expression is observed in the surface epithelium, including
the mammary placode epithelium (Figure 4e). By the E12.5
bud stage, Erbb3 expression is observed mostly in the surface
epithelium and in the epithelium flanking the mammary bud
and at lower levels within the bud proper (Figure 4f). At
E13.5, Erbb3 is expressed more strongly in epithelium
flanking the mammary bud and at very low levels in the
mammary bud (Figure 4g). At E14.5, Erbb3 is expressed in the
basal layer of the surface epithelium and at very low levels in
the mature mammary bud (Figure 4h).
Erbb4 is expressed in the anterior somites from E9 and in
all of the somites by E10.5 (Golding et al., 2004). At E11.0 to
E11.25, Erbb4 is expressed in the epaxial domain of the
somite and in the dermal mesenchyme above the somite
(Figure 5a–d). Erbb4 transcripts are present in the surface
epithelium along the flank, including that of the mammary
placode when it first appears and in the dermal mesenchyme
above the somite (Figure 5e and f). By E12.0, the mammary
placode and adjacent epithelium express Erbb4 and no
mesenchymal expression adjacent to the mammary placode
is observed (Figure 5h). Erbb4 expression is confined to the
bud proper and adjacent epithelium at the E12.0 to E12.5 bud
stages (Figure 5g and i). By E13.5, Erbb4 expression is
observed in the vicinity of the site of the future fat pad (data
not shown) and by E14.5, Erbb4 is barely detectable in the
mammary epithelium and expressed at moderate levels in the
surface epithelium (Figure 5k).
Localization of Nrg1, Nrg2, Nrg3, and Nrg4 during early
mammary morphogenesis
Nrg1 transcripts are present in the dermal mesenchyme
underlying the flank and in the overlying surface ectoderm at
the pre-mammary placode stage (Figure 6a and b). When the
placode is morphologically distinct, Nrg1 is highly expressed
in the dermal mesenchyme except for that directly underlying
the center of the placode, and is expressed in the dorsal and
ventral edges of the placode and in the adjacent epithelium
extending along the flank (Figure 6c and d). From E11.5 to
E12.5, Nrg1a is expressed very weakly in the mammary bud
epithelium and some expression is detected in the flanking
mesenchyme (Figure 6e and g). At E13.5, Nrg1a is expressed
at low levels in the surface and mammary bud epithelium and
in the dermal mesenchyme (Figure 6i). At E14.5, Nrg1a is
expressed in the surface epithelium and low levels of
mesenchymal expression are detected but not in the
mammary mesenchyme surrounding the mammary bud
(Figure 6k). At E11.5, E12.5, E13.5, and E14.5, Nrg1b
expression is detected in the surface epithelium flanking the
mammary bud and weak Nrg1b expression is observed
within the mammary epithelium; no mesenchymal Nrg1b
expression is observed (Figure 6f, h, j and l).
Nrg2 is weakly expressed in the epithelium along the flank
prior to formation of the mammary placode (Figure 7a and b).
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Figure 4. Erbb3 expression in the developing mammary gland. Expression
patterns at the site of mammary placodes from whole mount in situ with Erbb3
as probe. (a) E11.0, vibratome cross section (70 mm) across level where
number 3 mammary anlage will form. (b) The presumptive mammary region
is boxed and shown magnified in (b). Erbb3 is expressed in the dorsal root
ganglia, Schwann cells, surface epithelium overlying the Wolffian ridge
(arrowheads) and in the somite. (c) E11.5, vibratome cross section (70 mm)
across level of mammary placode number 1. The mammary region is boxed
and shown magnified in (d). Erbb3 is expressed in the mammary placode and
adjacent ventral epithelium (arrowheads) and in the somite. Erbb3 expression
at (e) E11.5 mammary placode 4, (f) E12.5 mammary bud 4, (g) E13.5
mammary bud 4, (h) E14.5 mammary bud 4. At E11.5 and E12.5, Erbb3 is
expressed in the surface epithelium of the mammary placode or bud
(arrowhead) and adjacent epithelium (arrows) (e and f). At E13.5, Erbb3 is
weakly expressed in the mammary epithelial bud (arrowhead) and higher
levels of Erbb3 expression are observed in the epithelia flanking the mammary
bud (arrows) (g). At E14.5, very low levels of Erbb3 are expressed in the
mammary epithelial bud (arrowhead) and low levels of Erbb3 expression are
observed in the basal surface epithelium (arrows) (h). drg, dorsal root ganglia;
sc, Schwann cells; s, somite. Bars¼ 600mm in (a); 150 mm in (b); 700 mm in
(c); 150mm in (d); 25 mm in (e); 35 mm in (f); 45 mm in (g); 55mm in (h).
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At the early placode stage, Nrg2 transcripts are present in the
epithelium along the flank in the surface epithelium of the
mammary placode (Figure 7c and d). Epithelial transcripts are
observed in similar pattern through the early bud stage
(Figure 7f). At E11.5, E12.5, and E13.5, very low levels of
Nrg2 expression are detected in the mammary and adjacent
epithelium (Figure 7e, g, and h). At E14.5, low levels of Nrg2
expression are detected in the mature mammary bud
epithelium and strong surface epithelial expression is
observed (Figure 7i).
Nrg3 is expressed in the dermal mesenchyme underlying
the flank prior to formation of the mammary placode; Nrg3
transcripts are more abundant at the ventral boundary of the
future site of the placode (Figure 8a and b). At the very late
pre-placode stage, just prior to when the placode first
appears, Nrg3 is expressed in the epithelium along the flank
and in the dermal mesenchyme underlying the site of the
placode (Figure 8c and d). We previously showed that Nrg3
expression becomes confined to the edges of the epithelium
of the mammary placode (Howard et al., 2005). At the
placode and early bud stage, Nrg3 is expressed only in the
mammary and adjacent surface epithelium (Figure 8f and g).
At the E13.5 bud stage, Nrg3 is expressed throughout the bud
epithelium and at the site of the future fat pad (Figure 8h). At
E14.5, Nrg3 is expressed moderately in the neck of the
mammary bud and adjacent surface epithelium. Nrg3 is also
expressed at the site of the future fat pad and at very low
levels throughout the mammary bud epithelium (Figure 8i).
At E11.0, Nrg4 is expressed in the epaxial domain of the
somite, no Nrg4 expression is detected in the epithelium and
very low levels of transcripts are detected in the mesenchyme
of the presumptive mammary region (Figure 9a and b).
At very late pre-placode stages, just prior to when the
mammary placode appears, Nrg4 is expressed in the
epithelium along the flank and in the dermal mesenchyme
underlying the site of the placode and in the epaxial, central,
and hypaxial domains of the somite (Figure 9c and d). At the
placode stage, Nrg4 is expressed in the dorsal and ventral
edge of the placode epithelium and in the dermal mesench-
yme spanning most of the flank except for directly under the
placode (Figure 9e and f). Nrg4 expression is detected in a
similar pattern in the E11.5 placode with slightly stronger
mesenchymal expression flanking the placode (Figure 9g). At
the E12.5 and E13.5 bud stages, Nrg4 expression is not
detected in the mammary bud epithelium and low levels are
detected in the surface epithelium (Figure 9h and i). Nrg4
expression is detected throughout the mammary mesench-
yme adjacent to the mammary bud (Figure 9h and i). At
E14.5, no Nrg4 expression is detected in the mature
mammary bud epithelium and moderate levels of Nrg4 are
detected in the mammary mesenchyme and in the surface
epithelium (Figure 9j).
DISCUSSION
Previous studies of the expression patterns of the Erbb
receptors during mammary gland development have focused
primarily on postnatal stages (Schroeder and Lee, 1998;
Darcy et al., 2000). Since our interest is in the inductive
events that lead up to the formation of the mammary placode,
we sought to determine the gene expression patterns during
embryogenesis. It seems highly likely that Erbb signaling
a
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Figure 5. Erbb4 expression in the developing mammary gland. Expression
patterns at the site of placode 3 from whole mount in situ with Erbb4 as probe.
(a) E11.0, vibratome cross section (70 mm) at the level where number 3
mammary anlage will form. The presumptive mammary region is boxed and
shown magnified in (b). (b) Erbb4 is expressed in the most ventral aspect of the
somite (arrowhead) and in the dermal mesenchyme (arrows). E11.25,
vibratome cross section (70mm) at the level where mammary placode number
3 will form (c). The presumptive mammary region is boxed and shown
magnified in (d). Erbb4 is expressed in the pre-placode epithelium
(arrowheads in (d)) and in the dermal mesenchyme (arrows in (d)). E11.5,
vibratome cross section (70mm) at the level where mammary placode number
3 is forming (e). The nascent mammary placode is boxed and shown
magnified in (f). Erbb4 is expressed in the surface epithelium of the
developing mammary placode and adjacent epithelium (arrowheads) and in
the dermal mesenchyme (arrow). Erbb4 expression at E12.0 mammary bud 4
(g), E12.5 mammary bud 4 (i), E13.5 mammary bud 4 (j), E14.5 mammary bud
2. Erbb4 expression at E12.0 and E12.5 shows weak expression in the
mammary epithelial bud (arrowhead) and adjacent epithelium (arrows) in
(g and i). (h) E12.0, vibratome cross section (70mm) of mammary placode
number 3 also shows epithelial expression of Erbb4 in (arrowhead) and
adjacent to the early mammary bud 3 (arrows). (i) At E13.5, Erbb4 is expressed
in the mammary bud (arrowhead) and adjacent epithelium (arrow). (j) By
E14.5, very weak Erbb4 expression is observed in the mammary bud
(arrowhead) and moderate levels of Erbb4 are expressed in the surface
epithelium (arrow and data not shown) and at the site of the future fat pad
(asterisks). s, somite. Bars¼ 600mm in (a); 150mm in (b); 325 mm in (c);
100mm in (d); 500 mm in (e); 100mm in (f); 30mm in (g); 40mm in (h); 40 mm
in (i); 45 mm in (j); 55 mm in (k).
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contributes to early mammary morphogenetic events since
multiple ligands and receptors of the pathway are expressed
at the sites of epithelial-mesenchymal interactions and are
known mediators of early mammary morphogenetic events
(Figure 10).
Nrg1a and Nrg1b are ligands for Erbb3 and Erbb4. Nrg2,
Nrg3, and Nrg4 are ligands for Erbb4. Erbb2 has no known
ligand but is the preferred heterodimerization partner for the
other Erbb receptors. Erbb3 lacks intrinsic kinase activity and
is only active when partnered with a heterodimer. Erbb4
signaling is further complicated by the existence of four
distinct isoforms that demonstrate differential activation of
downstream pathways and appear to mediate distinct
biological functional processes (Elenius et al., 1999; Rio
et al., 2000). The Erbb/Nrg network acts in an integrative
manner (Citri and Yarden, 2006). Signaling pathways such as
the phosphatidyl inositol 3-kinase pathway and mitogen-
activated protein kinase pathway are activated upon Erbb
receptor activation, which can then lead to a variety of
biological outcomes (Citri and Yarden, 2006). The effects that
occur upon Erbb receptor activation include cell prolifer-
ation, migration, differentiation, cell death and survival but
knowledge of precisely how particular cellular responses are
elicited is very limited. All of these cellular responses have
been implicated in the morphogenetic processes needed for
embryonic mammary development and have roles in breast
carcinogenesis.
Tissue recombination experiments suggest that the mesen-
chyme signals mammary placode formation (Propper and
Gomot, 1967; Sakakura, 1987; Cunha et al., 1995; Cunha
and Hom, 1996). Our functional studies have demonstrated
that Nrg3 can elicit mammary placode formation in
explanted embryos and suggest that Nrg3 functions as a
mesenchymal paracrine signal (Howard et al., 2005). It is,
therefore, of note that prior to the morphological appearance
of the placode, the receptors Erbb2, Erbb3, and Erbb4 and
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Figure 6. Nrg1 expression in the developing mammary gland. Expression patterns at the site of placode 3 from whole mount in situ with Nrg1 as probe.
(a) E11.0, vibratome cross section (70 mm) at the level where number 3 mammary anlage will form. The presumptive mammary region is boxed and shown
magnified in (b). Nrg1 is expressed in the epithelium (arrowheads in (b)) and in the epaxial domain of the somite (arrow in (a)) and adjacent dermal mesenchyme
along the Wolffian ridge. (c) E11.5, vibratome cross section (70 mm) at the level of mammary placode number 3. The mammary placode is boxed and
shown magnified in (d). Nrg1 is expressed in the somite (arrowheads in (c); epaxial expression denoted by arrow in (c)), in the surface epithelium of the
embryo and very intensely along the dorsal and ventral edges of the mammary placode (arrowheads in (d)) as well as in the dermal mesenchyme flanking the
mammary placode (arrows in (d)). Nrg1a expression at (e) E11.5 mammary placode 4, (g) E12.5 mammary bud 2, (i) E13.5 mammary bud 4, (k) E14.5
mammary bud 4. Nrg1b expression at (f) E11.5 mammary placode 4, (h) E12.5 mammary bud 2, (j) E13.5 mammary bud 4, (l) E14.5 mammary bud 2. Both
Nrg1a and Nrg1b are expressed at low levels in the E11.5 mammary placode and E12.5 mammary bud and adjacent surface epithelium (arrowheads in
(e, f, g and h)); low levels of Nrg1a expression are detected in the flanking mesenchyme (arrows in (e and g)). Nrg1a is expressed at low levels throughout most of
the mesenchyme (arrows) and in the mammary epithelium and flanking surface epithelium (arrowheads) at E13.5 (i). Nrg1b is expressed at low levels in surface
epithelium flanking the mammary bud (arrowheads) at E13.5 (j). At E14.5, Nrg1a is expressed at low levels throughout most of the mesenchyme (arrows) with the
exception of the mammary mesenchyme surrounding the mammary bud where no expression is detected; low levels of Nrg1a expression are detected in the
mammary bud epithelium and flanking surface epithelium (arrowheads) (k). At E14.5, low levels of Nrg1b expression are detected in the mammary bud
(arrowhead) and moderate levels of Nrg1b expression are detected in the surface epithelium (data not shown) (l). Bars¼ 300mm in (a); 300 mm in (b); 350 mm in
(c); 60 mm in (d); 25 mm in (e and f); 37.5 mm in (g and h); 45 mm in (i and j); 55 mm in (k and l).
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their ligands, Nrg1, Nrg3, and Nrg4 are all expressed in either
the somite, the dermal mesenchyme or in both tissues. Nrg1,
Nrg3, and Nrg4 could, therefore, contribute to mediating the
activation of Erbb 2:3, 2:4, 4:4, and 3:4 dimers within the
somites and Erbb 2:4 and 4:4 dimers within the dermal
mesenchyme. Nrg1, Nrg3, and Nrg4 would also be poised to
mediate signaling from the mesenchyme to the overlying
epithelium, which expresses all four Erbb receptors. Since
multiple isoforms of Nrg1, Nrg3, Nrg4 and Erbb4 also exist, it
is possible that distinct signals (that is, from the mesenchyme
to epithelium) are mediated by particular profiles of isoforms
(Falls, 2003; Hayes et al., 2007), Both membrane-bound and
secreted forms of the Erbb ligands exist. In some cases,
cleavage and release of the ligand from the membrane is
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E11.0 Nrg2
E11.5 Nrg2
E11.5 Nrg2
E12.0 Nrg2
E12.5 Nrg2
E13.5 Nrg2
E14.5 Nrg2
Figure 7. Nrg2 expression in the developing mammary gland. Expression
patterns at the site of placode 3 from whole mount in situ with Nrg2 as probe.
(a) E11.0, vibratome cross section (70 mm) at the level where number 3
mammary anlage will form. Nrg2 is expressed in some of the surface
epithelium (arrowhead) (a). No Nrg2 expression is observed in the
presumptive mammary region, which is boxed and shown magnified in (b).
(c) E11.5, vibratome cross section (70 mm) across level of mammary placode
number 3. The mammary region is boxed and shown magnified in (d).
(d) Nrg2 is expressed in the periderm of mammary placode and adjacent
epithelium (arrowheads). (f) E12.0, vibratome cross section (70 mm) at the
level of mammary bud number 3. Nrg2 is expressed in the surface epithelium
of the mammary bud (arrow) and in the adjacent epithelium (arrowheads)
(f). Nrg2 expression at (e) E11.5 mammary placode 3, (g) E12.5 mammary bud
4, (h) E13.5 mammary bud 4, (i) E14.5 mammary bud 2. Nrg2 is expressed at
very low levels in the mammary bud and adjacent epithelium (arrowheads) at
E11.5, E12.5, and E13.5 (h). Nrg2 expression is detected in nerves (arrows)
(g–i). At E14.5, Nrg2 is expressed at moderate to high levels in the mammary
bud and surface epithelium (arrowheads) and in nerves (arrow) (i).
Bars¼ 300 mm in (a); 150mm in (b) 700 mm in (c); 150 mm in (d); 60mm in (e);
25mm in (f); 30 mm in (g): 45mm in (h); 55 mm in (i).
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E11.0 Nrg3 E12.5 Nrg3
E13.5 Nrg3
E14.5 Nrg3
E11.25 Nrg3
E11.5 Nrg3
E11.5 Nrg3
Figure 8. Nrg3 expression in the developing mammary gland. (a) Expression
patterns at the site of placode 3 from whole mount in situ with Nrg3 as probe.
E11.0, vibratome cross section (70 mm) at the level where number 3 mammary
anlage will form. The presumptive mammary region is boxed and shown
magnified in (b). Nrg3 is expressed in the dermal mesenchyme along and
ventral to the Wolffian ridge (arrows in (a and b)). A few epithelial cells
located dorsally to the future site of the mammary placode express Nrg3
(arrowheads in (b)). (c) E11.25, vibratome cross section (70mm) across level of
mammary placode number 3 (arrow). Nrg3 is expressed in the dermal
mesenchyme above both the epaxial and hypaxial domains of the somite
(arrows). The mammary region is boxed and shown magnified in (d). At the
late pre-placode stage, Nrg3 is expressed in the epithelium along the site the
mammary placode will soon form and adjacent epithelium (arrowheads)
along the Wolffian ridge. (e) E11.5, vibratome cross section (70 mm) of
mammary placode number 3 shows epithelial expression of Nrg3 in the
nascent mammary placode 3. Nrg3 expression at (f) 11.5 mammary placode
3, (g) E12.5 mammary bud 4, (h) E13.5 mammary bud 4, (i) E14.5 mammary
bud 4. At E11.5 and E12.5, Nrg3 is expressed in the mammary epithelial
placode or bud (arrowheads in f and g) and adjacent epithelium (arrows in
f and g). At E13.5, Nrg3 is expressed at low to moderate levels in the mammary
bud (arrowhead) and at the site of the future fat pad (asterisks) (g). By E14.5,
Nrg3 is expressed at very low levels in the mammary bud (arrowhead) and at
higher levels in the neck of the bud (arrow) and the adjacent epithelium
(arrowhead); Nrg3 expression is detected in the future fat pad site (asterisks)
(i). Bars¼ 275mm in (a); 150mm in (b); 650mm in (c); 150mm in (d); 50mm in
(e); 37.5mm in (f); 40mm in (g); 45mm in (h); 55mm in (i).
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necessary for functional activity (Sternlicht et al., 2005). A
wide spectrum of signaling possibilities exists since it is
thought that specificity of response to Erbb ligands is
dependent on ligand concentration and the availability of
heterodimerization partners as well as ligand/receptor affi-
nities (Riese and Stern, 1998; Hobbs et al., 2002).
Nrg1, Nrg2, Nrg3, Erbb1, Erbb2, Erbb3, and Erbb4
expression within the mammary anlagen persists from the
time the placode forms to the later bud stages. Once the
placode has formed, Erbb1 and Erbb2 are the only Erbb
receptors expressed in the mesenchyme adjacent to the
mammary epithelium. None of the Erbb receptors are
detected in the primary mammary mesenchyme. Nrg4 is
the only ligand expressed in the mammary mesenchyme and
could therefore mediate mesenchymal-epithelial communi-
cation from the very earliest stages through to later mammary
development stages. Once the mammary placode has
formed, changes in the adhesive profile of the anlage
epithelium are thought to allow rearrangement of epithelial
cells during the mammary bud stages (Nanba et al., 2001).
Survival signals are also necessary to maintain the mammary
bud (Boras-Granic et al., 2006). Both cell proliferation and
apoptosis occur as the mammary bud develops (Michno
et al., 2003; Boras-Granic et al., 2006). Erbb signaling has
been linked to all of these cellular processes; based on the
expression of its components, it could potentially contribute
to any of them. Nrg1a acts as a motility factor released by
keratinocytes during wound healing and in Paget’s disease of
the nipple, and could possibly act to elicit local migration of
Erbb-expressing cells during mammary morphogenesis
(Schelfhout et al., 2000, 2002). Nrg1a, Nrg3, and Nrg4 are
expressed in the secondary mammary mesenchyme, the
future site of the fat pad, at later bud stages. Erbb1, Erbb2, and
Erbb4 are also detected and therefore could be responsible
for downstream signaling from these ligands at this stage.
During postnatal mammary development, Nrg1 is expressed
in the mammary stroma but not in mammary fat pads that
have been cleared of mammary epithelia (Yang et al., 1995).
This suggests that signals from the mammary epithelia are
required to sustain Nrg1 expression in the mammary stroma.
Our results suggest the dialog between the mammary
epithelium and future mammary stroma could begin during
embryogenesis.
Mammary buds form in the viable Erbb1 and Erbb3-null
models and in the genetically rescued Erbb2 and Erbb4-null
mice (in which heart-specific myosin promoters are used to
provide expression of the ablated genes to overcome
lethality), so it appears that signaling through any of the four
Erbb receptor homodimers is not required for inductive
events (Wiesen et al., 1999; Tidcombe et al., 2003; Jackson-
Fisher et al., 2004). However, embryonic mammary bud
phenotypes have not been analyzed, so it is unclear if they
develop normally in absence of particular Erbb homodimers.
Mammary ductal outgrowth is impeded when mammary
buds or tissue are isolated from either Erbb1 or Erbb2-null
mice and transplanted into cleared fat pads to analyze
epithelial outgrowths (Wiesen et al., 1999; Jackson-Fisher
et al., 2004). It is possible that mammary placode formation is
E11.0 Nrg4
E11.25 Nrg4
E11.5 Nrg4
E11.5 Nrg4
E14.5 Nrg4
E13.5 Nrg4
E12.5 Nrg4
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Figure 9. Nrg4 expression in the developing mammary gland. Expression
patterns at the site of placode 3 from whole mount in situ with Nrg4 as probe.
(a) E11.0, vibratome cross section (70mm) at the level where number 3 mammary
anlage will form. Nrg4 transcripts are detected in the epaxial domain of the
somite (arrow in (a)). The presumptive mammary region is boxed and shown
magnified in (b). No Nrg4 expression is detected in the epithelium and weak
expression in the lateral plate mesoderm is detected ventral to the future site of
the mammary placode (arrow in (b)). (c) E11.25, vibratome cross section (70mm)
at the level of mammary placode number 3. The epaxial somitic expression is
denoted by the arrow in (c) and Nrg4 expression extends the length of the somite
(c). The mammary region is boxed and shown in magnification in (d). (d) At the
late pre-placode stage,Nrg4 is expressed in the epithelium at the future site of the
mammary placode (arrowheads) and in the underlying dermal mesenchyme
(arrows) and in the somite. At the placode stage, E11.5, Nrg4 is expressed in the
somite (arrows in (e)) and in the epithelium at the dorsal and ventral edges of the
mammary placode (arrowheads in (f)) and in the dermal mesenchyme underlying
the epithelium directly adjacent to but not under the mammary placode (arrows
in (f)). Nrg4 expression at (g) E11.5 mammary placode 4, (h) E12.5 mammary bud
4, (i) E13.5 mammary bud 4, (j) E14.5 mammary bud 2. At E11.5, Nrg4 is
expressed in the mesenchyme adjacent to the mammary placode (arrows) and
diffusely throughout the dermal mesenchyme and at low levels in the surface and
mammary epithelium (arrowheads) (g). At E12.5, Nrg4 is expressed in the
mesenchyme surrounding the mammary bud (arrows) and at very low levels in
the surface epithelium (arrowheads) (h). At E13.5, Nrg4 is expressed in the
mammary mesenchyme surrounding the mammary bud (arrows) and some
expression is detected at the site of the future fat pad (asterisks); weak Nrg4
expression is detected in the surface epithelium adjacent to the mammary bud
(arrowheads), and no expression is detected in the mammary bud epithelium
(i). At E14.5, Nrg4 is expressed in the mammary mesenchyme surrounding the
mammary bud (arrows) and at the site of the future fat pad (asterisks); moderate
Nrg4 expression is detected in the surface epithelium (arrowheads and data not
shown), and no expression is detected in the mammary bud epithelium
(j). Bars¼ 600mm in (a); 150mm in (b); 650mm in (c); 150mm in (d); 700mm in
(e); 150mm in (f); 35mm in (g); 40mm in (h); 45mm in (i); 55mm in (j).
1016 Journal of Investigative Dermatology (2008), Volume 128
O Wansbury et al.
Erbb Network Expression in Mammary Anlagen
usually elicited through heterodimers and when one member
is not available, another compensates. Since members of the
Erbb signaling network may perform redundant or partially
redundant functions, the analysis of the effects of the total loss
of either Erbb or Neuregulin functions is likely to require the
generation of mice bearing multiple mutations. Further
functional studies, such as the very elegant analysis by
Sternlicht et al. (2005) that demonstrated the requirement
during mammary branching morphogenesis for paracrine
activation of stromal Egfr by epithelial Amphiregulin, will be
required to assign roles to Erbb pathway members.
Regulation of Erbb signaling components at both the
expression level and through other mechanisms, such as
feedback loops and receptor compartmentalization, are
implemented so that overexpression and overactivation of
the pathway are usually avoided (Citri and Yarden, 2006).
Erbb receptors are overexpressed and/or amplified and
activated frequently in human cancers and have been used
in developing targeted therapeutics that are now used
as clinical therapeutic agents (Zahnow, 2006; Bublil
and Yarden, 2007). Herceptin/trastuzumab, a humanized
monoclonal antibody against Erbb2/HER2, has been used
with impressive clinical results in the treatment of breast
cancers (Baselga et al., 1996; Cobleigh et al., 1999; Smith,
2001; Harries and Smith, 2002). Recently, it has become
apparent that the expression of Erbb/HER ligands also impacts
the clinical outcome of breast cancer patients treated with
Herceptin (de Alava et al., 2007). In this retrospective study,
patients with breast cancer tumors that expressed high levels
of transmembrane Nrg1 and low HER2 expression showed
greater time to disease progression and better overall survival
when treated with Herceptin when compared to those with
HER2-expressing tumors (de Alava et al., 2007). Other studies
have also suggested that some patients with breast cancers
that do not express HER2 also benefit from Herceptin
treatment (Vogel et al., 2002). These finding underscores
the importance of understanding the roles of both ligand and
receptor in the normal tissue, as it is possible that this may
serve as a paradigm for other Erbb-based therapeutics.
We have recently found that mis-expressing Nrg3 through-
out the developing epidermis using the K14 promoter in a
transgenic mouse model results in the formation of ectopic
Pre-placode E11.0
Erbb1
Erbb2
Erbb3
Erbb4
Nrg1
Nrg2
Nrg3
Nrg4
Placode E11.5 Early bud E12.5 Late bud E13.5 Mature bud E14.5
Figure 10. Summary of the distribution of Erbb signaling molecules during early mammary morphogenesis. Transcript localization is determined by
whole-mount in situ hybridization for mammary pre-placode and placode stages. Expression in mammary bud stages is determined by immunohistochemistry.
Moderate and high levels of epithelial expression are represented by solid green. Low levels or diffuse expression are denoted by a patterned green. Solid
dark blue represents high levels of mesenchymal expression. Dark blue diamonds denote low or moderate levels of dispersed mesenchymal expression.
Solid gray denotes expression at the future fat pad site. The basement membrane is denoted by black line; the site of the future fat pad is denoted by a
rectangle; the mammary mesenchyme is denoted by the concentric rings around the mammary bud; the developing mammary anlagen are shown so that
dorsal is left and ventral is right.
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mammary glands (Panchal et al., in press). Other epidermal
phenotypes are also observed in this mouse model, which are
similar to those found in transgenic mouse models that
deregulate c-Myc expression in the developing epidermis
using the K14 promoter (Arnold and Watt, 2001; Waikel
et al., 2001; Frye et al., 2003). In addition to increased c-Myc
expression in the transgenic epidermis, we observe decreased
expression of the adhesion receptors, a6-integrin and b1-
integrin. Cell-cell and cell-matrix interactions regulate
epithelial organization. Desmosomal and hemidesmosomal
expression profiles are downregulated during early mammary
bud formation and are thought to mediate differences in cell
adhesive properties within the forming bud and are subse-
quently restored during later stages of mammary gland
formation (Nanba et al., 2001). Downregulation of E-
cadherin mediated by a Wnt signal and Noggin also results
in decreased cell adhesion in the epidermis and has been
proposed as a general mechanism that mediates morphogen-
esis of all budding organs (Jamora et al., 2003). It is possible
that epithelial cells that will form the mammary placode
respond to the inductive signals from the dermal mesen-
chyme by changing their cell adhesion properties to effect early
morphogenesis, although this remains to be demonstrated.
Deregulated cell organization and disrupted cell polarity
are features of most epithelial cancers, including breast
cancers. Integrins are structural proteins that interact with the
extracellular matrix and play key roles in regulating epithelial
adhesion, growth and differentiation (Watt, 2002). a6b4
integrin is concentrated at hemidesmosomes, which mediate
attachment of epithelial cells to the basement membrane
(Sonnenberg et al., 1991). Most breast tumors lack hemi-
desmosomes and exhibit diffuse and elevated expression of
a6b4 integrin rather than the basal expression that is observed
in normal epithelial cells (Mercurio et al., 2001; Wilhelmsen
et al., 2006). Altered a6b4 integrin expression is associated
with poor prognosis in breast cancer patients (Tagliabue
et al., 1998). a6b4 integrin is thought to promote cell
migration by stabilizing dynamic structures such as lamelli-
podia (Rabinovitz et al., 1999; Gagnoux-Palacios et al.,
2003). Integrins can initiate and modulate signals by forming
a cooperative signaling network with receptor tyrosine
kinases to regulate a variety of biological processes (Hynes,
2002; Miranti and Brugge, 2002; Gagnoux-Palacios et al.,
2003). Recent studies of the Erbb2 mouse model of
tumorigenesis have led to advancements in our under-
standing in how aberrant Erbb receptor signaling alters
mammary epithelium so that tumorigenesis is promoted.
The a6b4 integrin cooperates with Erbb2 in the formation of
mammary tumors (Guo et al., 2006). b4 integrin is thought to
form a complex with Erbb2 and promotes tumor progression
by amplifying Erbb2 signaling, which results in disrupted
epithelial polarity and hyperproliferation tumors (Guo et al.,
2006). Many other studies have also shown that significant
cross-talk exists between Erbb members and integrins, which
can contribute to breast cancer progression (Falcioni et al.,
1997; Siegel et al., 1999; Gambaletta et al., 2000; Yoon
et al., 2006a, b; Folgiero et al., 2007). Further elucidation of
the link between integrins and receptor tyrosine kinases will
lead to a deeper understanding that is relevant to both
developmental and cancer biology.
In summary, Nrg1, Nrg2, Nrg3, and Nrg4 are expressed in
patterns during early mammary morphogenesis that suggest
they could mediate intra-epithelial or intra-mesenchymal
signals within tissues and epithelial-mesenchymal interac-
tions with adjacent tissues expressing Erbb2, Erbb3 and
Erbb4. Egf and Egf-related ligands (Tgfa, Amphiregulin,
Betacellulin, and HB-EGF) are ligands for Erbb1, which have
not been examined in this study. Therefore it is not clear what
type of signals they might mediate. The expression patterns
observed in this study suggest that an Erbb juxtacrine
signaling network may mediate epithelial and mesenchymal
interactions during early mammary morphogenetic events
and that autocrine/paracrine loops may also exist. Somitic
Nrg/Erbb signals may also be involved in early mammary
morphogenesis as has recently been elegantly demonstrated
with Fgf10 (Veltmaat et al., 2006). Both embryonic and
postnatal mammary gland development rely on intercellular
communication within the epithelium and between epithelial
and mesenchymal cells. On the basis of the expression
patterns reported here and in conjunction with their known
roles in postnatal mammary development, the Erbb network
members are candidates for some of the signals that operate
during early mammary morphogenetic events.
Conclusions
This molecular histology study defines the spatial and
temporal expression pattern of key members of the Erbb
signaling network during mammary placode and bud
morphogenesis. The expression patterns suggest that multiple
members of the Erbb network could mediate and modulate
early mammary morphogenetic events.
MATERIALS AND METHODS
Whole-mount in situ hybridization
All mouse studies have been approved by the Institute of Cancer
Research’s Ethics Board. Mouse embryos were from timed C57BL/6
(B6) matings. In situ hybridization protocols were as described
(Wilkinson and Nieto, 1993). Two to four embryos were analyzed
for each probe for each of the shown stages. Digoxigenin-labelled
sense and anti-sense RNA was synthesized following standard
protocols (Roche, Mannheim, Germany). Anti-sense and sense
probes were generated from plasmids containing mouse DNA:
Erbb1 probe corresponding to nucleotides (nt) 1146–2028 of
Genbank accession no. NM_007912; Erbb2 probes corresponding
to nt 2483–3453 or 2722–3453 of Genbank accession no.
NM_001003817; Erbb3 probe corresponding to nt 1342–2455 of
Genbank accession no. NM_010153; Erbb4 probe corresponding to
nt 558–1527 of Genbank accession no. XM_136682; the Nrg1 probe
detects transcripts corresponding to nt 667–1242 of Genbank
accession no. NM_178591 (Hrga) and 126–1077 of AY648976
(Hrg1b); Nrg2 probe corresponding to nt 1253-2068 of Genbank
accession no. XM_001063076; Nrg3 probes corresponding to nt
1242–1922 of Genbank accession no. NM_008734; Nrg4 probe
corresponding to nt 63–621 of Genbank accession no. NM_032002.
A sense probe for each probe gave no specific signal (Figure S1).
Whole mount in situ hybridization was performed as described
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previously (Howard et al., 2005). Embryos were sectioned by
embedding in agarose and cutting 70-mm sections using a vibratome.
Immunohistochemistry
Time-mated B6 mouse embryos were fixed overnight in 4%
paraformaldehyde, formalin, or Carnoy’s and then paraffin em-
bedded. At least three embryos were analyzed for each of the shown
stages. Sections (5mm) were rehydrated and processed with
microwave antigen retrieval if required. After incubation in 3%
H2O2 in methanol to block endogenous peroxidases, sections were
rinsed and incubated in Dako blocking buffer for 10minutes to block
non-specific binding. Primary antibodies were diluted in 5% BSA/
0.5% Tween 20 and sections were incubated with primary
antibodies overnight at room temperature.
The primary antibodies at the indicated dilutions were: goat
polyclonals: Nrg3 (1:500; R&D Systems, Minneapolis, MN), Nrg3
(1:500; Santa Cruz, Santa Cruz, CA, P-18), Nrg3 (1:500; Santa Cruz,
D19) Nrg4 (1:50 Santa Cruz, L-16), rabbit polyclonals; Erbb2 (1:50;
Santa Cruz, C-18), Erbb3 (1:100; Santa Cruz, C-17), Erbb4 (1:300;
Santa Cruz, C-18), Nrg1a (1:75 LabVision, Fremont, CA, Ab-3),
Nrg1b; 1:25; Santa Cruz, C-20) Nrg2 (1:25, Abgent, San Diego, CA),
Nrg3 (1:50; Abgent), sheep polyclonal; EGFR (1:50; Upstate, Lake
Placid, NY). Control experiments were performed in which primary
antibodies were preincubated with blocking peptide or were left
out of the procedure (Figure S2). Expression at other sites within the
embryo was used for a positive control. Since no blocking peptide is
available for the EGFR antibody, we have provided both in situ and
immunohistochemical stain at E11.5, E12.5, and E13.5. For the other
markers, a vibratome section of the mammary placode used in the
whole-mount in situ hybridization and a section at a similar stage
used in the immunochemistry study is included to demonstrate the
validity of the reagents.
Peroxidase-labeled polymer (Envision rabbit, Dako, Glostrup,
Denmark) was used for detection of primary antibodies raised in
rabbits. Biotin-labeled donkey anti-goat IgG antibody (Invitrogen,
Eugene, OR) was used for detection of the goat antibodies using
Vector ABC kit (Vector Labs, Burlingame, CA) or Goat Histofine
Simple Stain MAX PO (Nicherei). Biotin-labeled rabbit anti-sheep
IgG antibody (Vector Labs) was used for detection of the sheep
antibodies. 3,30-diaminobenzidine was used as chromagen and
sections were counterstained with hematoxylin.
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